Person:
SEVİK, MEHMET ORKUN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

SEVİK

First Name

MEHMET ORKUN

Name

Filters

20181
Reset filters

Settings

End date: 2018 × Start date: 2018 ×

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    Topical Treatment of Persistent Epithelial Defects with a Matrix Regenerating Agent
    (MARY ANN LIEBERT, INC, 2018) TOKER, AYŞE EBRU; Sevik, Mehmet Orkun; Turhan, Semra Akkaya; Toker, Ebru
    Purpose: The aim of the study was to assess the efficacy of a topical regenerating agent (RGTA) for management of persistent epithelial defects (PEDs) resistant to conventional therapy. Methods: Twenty-one patients (23 eyes) with PEDs despite the use of conventional therapy for lagophthalmos (n = 4), neurotrophic ulcer (n = 9), chemical burn (n = 3), Stevens-Johnson syndrome (n = 1), atopic keratoconjunctivitis (n = 1), severe dry eye (n = 2), peripheral ulcerative keratitis (n = 1), fungal keratitis (n = 1), and bacterial keratitis (n = 1) were enrolled in the study. Patients were treated with RGTA (Cacicol; Thea, Paris, France) instilled at a dosage of one drop on alternate days. Patients were evaluated by slit-lamp examination, anterior segment photography, and fluorescein-dye testing. Ulcer areas were noted on alternate days starting from the first day of instillation. Results: Twenty of 23 eyes (86.9%) displayed complete corneal healing after a mean period of similar to 7.2 days (range, 2-20 days). Mean decrease ratio of ulcer area observed was 61.2% (range, 8.8%-100%, n = 19) on the 2nd day, 74.4% (range, 36%-100%, n = 16) on the 4th day, 80.2% (range, 43.7%-100%, n = 12) on the 6th day, 88.5% (range, 55.9%-100%, n = 9) on the 8th day, and 85.5% (range, 58.3%-100%, n = 7) on the 10th day. No significant differences were found in the epithelialization speed between eyes with and without bandage contact lenses in any postoperative day (P > 0.05). There were no treatment-related local or systemic side effects during the study. Conclusions: RGTA seems to be an effective therapeutic alternative in the treatment of persistent corneal epithelial defects.